CanSinoBIO says filed application in China for COVID-19 vaccine approval
In this article:
Feb 24 (Reuters) - CanSino Biologics Inc said on Wednesday it has filed an application in China to seek approval of its COVID-19 vaccine after global trials of the shot showed positive results.
CanSino said the interim analysis of data from its multi-country trial showed that its candidate, known as Ad5-nCoV, has an efficacy rate of 65.28% at preventing all symptomatic cases and 90.07% at preventing severe disease 28 days after a single dose has been given. (Reporting by Anushka Trivedi in Bengaluru; Editing by Christian Schmollinger)
